For example, PARP1, a PARP inhibitor, creates synthetic lethality in HR-deficient cancers, such as breast and ovarian tumors harboring BRCA1 and BRCA2 gene mutations [2, 4, 6]. This evidence concerns the gene PARP1 and cancer.